AngioDynamics (ANGO) Reports In-Line Q1 EPS, Offers Q2 and FY16 Guidance

AngioDynamics (NASDAQ: ANGO) reported Q1 EPS of $0.11, in-line with the analyst estimate of $0.11. Revenue for the quarter came in at $83.7 million versus the consensus estimate of $84.7 million.

AngioDynamics sees Q2 2016 EPS of $0.13-$0.15, versus the consensus of $0.16. AngioDynamics sees Q2 2016 revenue of $87-91 million, versus the consensus of $91.98 million.

AngioDynamics sees FY2016 EPS of $0.62-$0.63, versus the consensus of $0.64. AngioDynamics sees FY2016 revenue of $364-370 million, versus the consensus of $365.23 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• Phibro Animal Health (PAHC) Tops Q4 EPS by 13c; Offers Guidance
• Okta, Inc. (OKTA) Tops Q2 EPS by 8c; offers guidance
• Salesforce (CRM) Tops Q2 EPS by $2.63, Offers Guidance